Will FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?

Market shows low confidence in FDA approval of mRNA herpes vaccines by 2028.

The prediction market indicates a 25% probability of FDA approval for any mRNA vaccine targeting herpes simplex infections before 2028, with a stronger consensus against it. The Pulse AI probability slightly favors approval at 28.5%, but overall confidence remains moderate at 50 out of 100. The market appears fairly priced, suggesting limited expectations for significant developments in this area soon.

• 1 Current market sentiment leans heavily towards NO approval.
• 2 The probability gap between market and AI suggests cautious optimism.
• 3 Historical data on vaccine approvals may influence perceptions.
• 4 Liquidity in the market appears stable, reflecting balanced opinions.
• 5 Time to expiry indicates a long wait for potential developments.